Does the commercial support system — as it exists today — inevitably compromise CME's independence? That's the question the Accreditation Council for CME will explore over the next year as it conducts its first-ever big-picture review of the funding process. It will examine a range of options, from leaving the system intact, to setting up a centralized grants repository, to limiting — or even prohibiting — pharmaceutical industry funding of CME. Since drug companies funnel about $1 billion ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the Rethinking the Lifeline, you'll also gain access to exclusive premium content.

Already registered? here.